| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 3.0K | 5.1% | 10.2% |
| Total Income | 3.0K | 5.1% | 10.2% |
| Expenditure | 2.6K | 3.5% | 11.2% |
| PBT | 412.00 | 23.4% | 7.3% |
| Net Profit | 320.00 | 27.0% | 13.5% |
| OPM | 15.08% | 1.30pp | 0.78pp |
| NPM | 10.52% | 1.81pp | 0.30pp |
| EPS | 2.88 | 26.9% | 14.7% |
Quest Diagnostics Reports Q2 2026 Financial Results; Raises Full Year Guidance
23 Jul 2026 · 23 Jul, 4:21 pm
Summary
Quest Diagnostics reported strong second quarter 2026 financial results, with revenues of $3.04 billion, up 10.2% year-over-year, primarily driven by 10.0% organic growth. The company also saw significant increases in profitability, with reported diluted EPS rising 15.0% to $2.84 and adjusted diluted EPS up 19.1% to $3.12. Based on this performance and sustained demand, Quest Diagnostics has raised its full-year 2026 guidance for both revenue and earnings per share.
Key Highlights
- 1
Second quarter revenues reached $3.04 billion, marking a 10.2% increase from the prior year, driven by 10.0% organic revenue growth.
- 2
Reported diluted earnings per share (EPS) for the second quarter were $2.84, a 15.0% increase year-over-year.
- 3
Adjusted diluted EPS in the second quarter grew by 19.1% to $3.12 compared to the prior year.
- 4
The company has raised its full year 2026 revenue guidance to be between $11.95 billion and $12.05 billion.
- 5
Full year 2026 reported diluted EPS is now expected to be between $9.97 and $10.17.
- 6
Adjusted diluted EPS for the full year 2026 is now projected to be between $11.05 and $11.25.
Management Comments
Jim Davis
Our robust top- and bottom-line growth in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate paths for better health. Revenues increased by over 10%, almost all from organic revenue growth across our physician, hospital and consumer channels, and adjusted diluted EPS grew over 19%. With strong growth and sustained demand for our diagnostic insights, we are again raising our full year guidance.
Informational and educational content only. Not investment advice.